198 related articles for article (PubMed ID: 33068053)
1. Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects.
Cui C; Valerie Sia JE; Tu S; Li X; Dong Z; Yu Z; Yao X; Hatley O; Li H; Liu D
Br J Clin Pharmacol; 2021 Jul; 87(7):2711-2722. PubMed ID: 33068053
[TBL] [Abstract][Full Text] [Related]
2. Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults.
Li GF; Zheng QS; Yu Y; Zhong W; Zhou HH; Qiu F; Wang G; Yu G; Derendorf H
Clin Pharmacokinet; 2019 Jul; 58(7):927-941. PubMed ID: 30767128
[TBL] [Abstract][Full Text] [Related]
3. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.
Barter ZE; Tucker GT; Rowland-Yeo K
Clin Pharmacokinet; 2013 Dec; 52(12):1085-100. PubMed ID: 23818090
[TBL] [Abstract][Full Text] [Related]
4. Development of a Virtual Chinese Pediatric Population Physiological Model Targeting Specific Metabolism and Kidney Elimination Pathways.
Yao X; Liu X; Tu S; Li X; Lei Z; Hou Z; Yu Z; Cui C; Dong Z; Salem F; Li H; Liu D
Front Pharmacol; 2021; 12():648697. PubMed ID: 34045960
[No Abstract] [Full Text] [Related]
5. Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration.
Wang HY; Chen X; Jiang J; Shi J; Hu P
Acta Pharmacol Sin; 2016 Feb; 37(2):276-84. PubMed ID: 26592516
[TBL] [Abstract][Full Text] [Related]
6. Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
Konishi K; Minematsu T; Nagasaka Y; Tabata K
Biopharm Drug Dispos; 2019 May; 40(5-6):176-187. PubMed ID: 30985942
[TBL] [Abstract][Full Text] [Related]
7. Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy.
Abduljalil K; Pansari A; Jamei M
J Pharmacokinet Pharmacodyn; 2020 Aug; 47(4):361-383. PubMed ID: 32840724
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravenous ibuprofen pharmacokinetics between Caucasian and Chinese populations using physiologically based pharmacokinetics modeling and simulation.
Jin Y; Zhang M; Di X; Qi X; Zheng L; Wang Z
Eur J Pharm Sci; 2023 Dec; 191():106587. PubMed ID: 37734467
[TBL] [Abstract][Full Text] [Related]
9. Development and Verification of a Japanese Pediatric Physiologically Based Pharmacokinetic Model with Emphasis on Drugs Eliminated by Cytochrome P450 or Renal Excretion.
Johnson TN; Abduljalil K; Pan X; Emoto C
J Clin Pharmacol; 2023 Oct; 63(10):1156-1168. PubMed ID: 37496106
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations.
Yu Y; Lin J; Muto C; Li Y; Mori Y; Mittapalli RK; Tse S; Liu J; Ge BK; Liu J
Int J Med Sci; 2021; 18(16):3718-3727. PubMed ID: 34790045
[TBL] [Abstract][Full Text] [Related]
11. Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.
Polasek TM; Tucker GT; Sorich MJ; Wiese MD; Mohan T; Rostami-Hodjegan A; Korprasertthaworn P; Perera V; Rowland A
Br J Clin Pharmacol; 2018 Mar; 84(3):462-476. PubMed ID: 29194718
[TBL] [Abstract][Full Text] [Related]
12. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Narayanan R; Hoffmann M; Kumar G; Surapaneni S
Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
[TBL] [Abstract][Full Text] [Related]
13. A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.
Gaohua L; Abduljalil K; Jamei M; Johnson TN; Rostami-Hodjegan A
Br J Clin Pharmacol; 2012 Nov; 74(5):873-85. PubMed ID: 22725721
[TBL] [Abstract][Full Text] [Related]
14. Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.
Feng S; Cleary Y; Parrott N; Hu P; Weber C; Wang Y; Yin OQ; Shi J
Eur J Clin Pharmacol; 2015 May; 71(5):617-24. PubMed ID: 25801493
[TBL] [Abstract][Full Text] [Related]
15. Preliminary physiologically based pharmacokinetic modeling of renally cleared drugs in Chinese pregnant women.
Song L; Yu Z; Xu Y; Li X; Liu X; Liu D; Zhou T
Biopharm Drug Dispos; 2020 Jun; 41(6):248-267. PubMed ID: 32520400
[TBL] [Abstract][Full Text] [Related]
16. Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population.
Abduljalil K; Pan X; Pansari A; Jamei M; Johnson TN
Clin Pharmacokinet; 2020 Apr; 59(4):501-518. PubMed ID: 31587145
[TBL] [Abstract][Full Text] [Related]
17. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
18. Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.
Rhee SJ; Chung H; Yi S; Yu KS; Chung JY
Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):973-980. PubMed ID: 28536774
[TBL] [Abstract][Full Text] [Related]
19. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
20. Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients.
Cui C; Li X; Liang H; Hou Z; Tu S; Dong Z; Yao X; Zhang M; Zhang X; Li H; Zuo X; Liu D
Biopharm Drug Dispos; 2021 Jan; 42(1):24-34. PubMed ID: 33340419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
